EDMONTON, Nov. 16 /CNW/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Professor Hans-Peter Hartung as National Coordinator in Germany for the ongoing pivotal phase II/III trial of its lead drug, MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis. Professor Hartung is also a member of the Clinical Advisory Group for the international phase II/III trial.
